We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

956:HKEXChina Suntien Green Energy Corporation Limited Class H Analysis

Data as of 2026-06-18 - not real-time

SAR 7.90

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

AlMuneef trades around SAR 7.90, yet its discounted cash‑flow fair value is only SAR 2.11, indicating a substantial overvaluation. The stock’s trailing P/E of 12.34 is modest, but the negative revenue growth of 5.4% and thin gross margin of 14.8% raise concerns about earnings sustainability. Dividend yield of 3.16% looks attractive, supported by a comfortable payout ratio of 39% and strong operating cash flow, while the balance sheet remains solid with low debt (debt‑to‑equity 2.79) and ample cash reserves. Technical signals are mixed: the 20‑day SMA (7.98) sits just below the price, the MACD is marginally bearish, and RSI at 45 suggests no clear momentum, all compounded by a decreasing volume trend.
The company operates in the basic‑materials/agricultural‑inputs sector, which faces medium‑level commodity and regulatory exposure, and its geographic concentration in Saudi Arabia adds moderate geopolitical risk. Given the pronounced valuation gap, stagnant growth, and liquidity constraints, the outlook leans toward caution despite the dividend appeal.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Significant overvaluation relative to DCF
  • Neutral technical stance with bearish MACD
  • Decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Attractive dividend yield and sustainable payout
  • Low debt and strong cash generation
  • Ongoing revenue decline and thin margins

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF suggests price should be ~SAR 2.1 versus current SAR 7.9
  • Negative revenue growth and modest profitability
  • Medium sector and regulatory risks with limited upside

Key Metrics & Analysis

Financial Health

Revenue Growth-5.40%
Profit Margin10.29%
P/E Ratio12.3
ROE21.36%
ROA8.95%
Debt/Equity2.79
P/B Ratio2.5
Op. Cash FlowSAR25.1M
Free Cash FlowSAR3.9M

Technical Analysis

TrendNeutral
RSI45.3
SupportSAR 7.45
ResistanceSAR 8.49
MA 20SAR 7.98
MA 50SAR 8.15
MA 200SAR 7.77
MACDBearish
VolumeDecreasing
Fear & Greed Index90.82

Valuation

Fair ValueSAR 2.11
GradeOvervalued
TypeValue
Dividend Yield3.16%

Risk Assessment

Beta0.11
Volatility26.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.